Based on the study results to date, Eagle intends to further explore an investigational indication for Ryanodex for the treatment of hematopoietic syndrome in individuals exposed to high doses of radiation, such as nuclear power plant leakage or nuclear weapons.
The company plans to conduct further research for treatment of post-irradiation hematopoietic syndrome, which could include treating the hematological side effects in certain cancer patients undergoing radiation therapy.
Cancer biotech company Partner Therapeutics Inc reported on Wednesday the receipt of the US FDA's approval for Leukine (sargramostim) for the treatment of adult and pediatric patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome
of Acute Radiation Syndrome, or H-ARS).
Lee et al., "Mitigating effects of hUCBMSCs on the hematopoietic syndrome
resulting from total body irradiation," Experimental Hematology, vol.
(12) Persons undergoing the hematopoietic syndrome are susceptible to infection due to injury to the hematopoietic and immune systems.
Evaluating the risk of death via the hematopoietic syndrome mode for prolonged exposure of nuclear workers to radiation delivered at very low rates.
The hematopoietic syndrome
occurs after exposure to high-dose ionizing radiation, such as whole body exposure to 4-8 Gy (4-8 Sievert), with death occurring 30-60 days post exposure from complications associated mostly with bone marrow failure leading to severe anemia, hemorrhages and failure of the immune system.